{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:53:36Z","timestamp":1791287616181,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03062-1","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:18:52Z","timestamp":1791285532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-9955","authenticated-orcid":false,"given":"Lars Klingen","family":"Gj\u00e6rde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Peczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9739-0816","authenticated-orcid":false,"given":"William","family":"Boreland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sengel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bordat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3362-5814","authenticated-orcid":false,"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-8239","authenticated-orcid":false,"given":"Helene","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-7305","authenticated-orcid":false,"given":"Charlotte","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-036X","authenticated-orcid":false,"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-0114","authenticated-orcid":false,"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3062_CR1","doi-asserted-by":"crossref","unstructured":"Duarte RF, Sanchez-Ortega I. HCT in Elderly Patients. In: Sureda A, Corbacioglu S, Greco R, Kroger N, Carreras E (eds). The EBMT handbook: hematopoietic cell transplantation and cellular therapies, 8th edn. Springer International Publishing: Cham, 2024, pp 601-606.","DOI":"10.1007\/978-3-031-44080-9_68"},{"key":"3062_CR2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156\u201364. https:\/\/doi.org\/10.1182\/blood-2017-03-772368.","journal-title":"Blood"},{"key":"3062_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101243","volume":"34","author":"D Weisdorf","year":"2021","unstructured":"Weisdorf D. How old is too old for a transplant? Best Pract Res Clin Haematol. 2021;34:101243. https:\/\/doi.org\/10.1016\/j.beha.2021.101243.","journal-title":"Best Pract Res Clin Haematol"},{"key":"3062_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","volume":"31","author":"SR Spellman","year":"2025","unstructured":"Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, et al. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR. Transpl Cell Ther. 2025;31:505\u201332. https:\/\/doi.org\/10.1016\/j.jtct.2025.05.014.","journal-title":"Transpl Cell Ther"},{"key":"3062_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41409-025-02692-1","volume":"60","author":"A Piekarska","year":"2025","unstructured":"Piekarska A, Abouqateb M, Boreland W, Peczynski C, Zaucha JM, Kroger N, et al. Improved GVHD-free relapse-free survival when rATG\/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party. Bone Marrow Transpl. 2025;60:1574\u201383. https:\/\/doi.org\/10.1038\/s41409-025-02692-1.","journal-title":"Bone Marrow Transpl"},{"key":"3062_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/ejh.13030","volume":"100","author":"IS Moiseev","year":"2018","unstructured":"Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI, et al. Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations. Eur J Haematol. 2018;100:395\u2013402. https:\/\/doi.org\/10.1111\/ejh.13030.","journal-title":"Eur J Haematol"},{"key":"3062_CR7","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","volume":"10","author":"NS Nunes","year":"2019","unstructured":"Nunes NS, Kanakry CG. Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668 https:\/\/doi.org\/10.3389\/fimmu.2019.02668.","journal-title":"Front Immunol"},{"key":"3062_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MOH.0000000000000882","volume":"32","author":"F Barriga","year":"2025","unstructured":"Barriga F. Antithymocyte globulin and posttransplant cyclophosphamide in graft vs. host disease prophylaxis: comparison or combination. Curr Opin Hematol. 2025;32:301\u20137. https:\/\/doi.org\/10.1097\/MOH.0000000000000882","journal-title":"Curr Opin Hematol"},{"key":"3062_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102944","volume":"150","author":"X Lv","year":"2020","unstructured":"Lv X, Qi J, Zhou M, Shi B, Cai C, Tang Y, et al. Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: a multiple-treatments network meta-analysis. Crit Rev Oncol Hematol. 2020;150:102944. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102944.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3062_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2020.271445","volume":"107","author":"R Massoud","year":"2022","unstructured":"Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, et al. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. Haematologica. 2022;107:857\u201367. https:\/\/doi.org\/10.3324\/haematol.2020.271445.","journal-title":"Haematologica"},{"key":"3062_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"E Brissot","year":"2024","unstructured":"Brissot E, Labopin M, Labussi\u00e8re H, Fossard G, Chevallier P, Guillaume T, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 2024;14:31. https:\/\/doi.org\/10.1038\/s41408-024-00990-3.","journal-title":"Blood Cancer J"},{"key":"3062_CR12","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1182\/bloodadvances.2024013468","volume":"8","author":"Y Chalandon","year":"2024","unstructured":"Chalandon Y, Eikema DJ, Moiseev I, Ciceri F, Koster L, Vydra J, et al. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms. Blood Adv. 2024;8:4792\u2013802. https:\/\/doi.org\/10.1182\/bloodadvances.2024013468.","journal-title":"Blood Adv"},{"key":"3062_CR13","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"AH Bazarbachi","year":"2024","unstructured":"Bazarbachi AH, Labopin M, Raiola AM, Blaise D, Arcese W, Santarone S, et al. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: a report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer. 2024;130:3123\u201336. https:\/\/doi.org\/10.1002\/cncr.35365.","journal-title":"Cancer"},{"key":"3062_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00277-025-06199-z","volume":"104","author":"X Jin","year":"2025","unstructured":"Jin X, Yang Y, Chen X. Post-transplant cyclophosphamide versus anti-thymocyte globulin in haploidentical stem cell transplantation: a systematic review and meta-analysis. Ann Hematol. 2025;104:1317\u201328. https:\/\/doi.org\/10.1007\/s00277-025-06199-z.","journal-title":"Ann Hematol"},{"key":"3062_CR15","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41409-025-02678-z","volume":"60","author":"I Moiseev","year":"2025","unstructured":"Moiseev I, Abouqateb M, Peczynski C, Busca A, Kroger N, Cerretti R, et al. Post-transplantation cyclophosphamide and antithymocyte globulin in 8\/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT. Bone Marrow Transpl. 2025;60:1426\u201335. https:\/\/doi.org\/10.1038\/s41409-025-02678-z.","journal-title":"Bone Marrow Transpl"},{"key":"3062_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01032-8","volume":"14","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Gulbas Z, Gedde-Dahl T, et al. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J. 2024;14:45. https:\/\/doi.org\/10.1038\/s41408-024-01032-8.","journal-title":"Blood Cancer J"},{"key":"3062_CR17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood.2019000487","volume":"134","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia G, Labopin M, Kroger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892\u20139. https:\/\/doi.org\/10.1182\/blood.2019000487.","journal-title":"Blood"},{"key":"3062_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3324\/haematol.2024.287157","volume":"111","author":"J Bordat","year":"2026","unstructured":"Bordat J, Kaphan E, Robin M, Xhaard A, De Fontbrune FS, Chevillon F, et al. Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation. Haematologica. 2026;111:546\u201357. https:\/\/doi.org\/10.3324\/haematol.2024.287157.","journal-title":"Haematologica"},{"key":"3062_CR19","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","volume":"38","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Kroger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. 2024;38:1156\u201363. https:\/\/doi.org\/10.1038\/s41375-024-02225-7.","journal-title":"Leukemia"},{"key":"3062_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1071268","volume":"13","author":"L Tang","year":"2023","unstructured":"Tang L, Liu Z, Li T, Dong T, Wu Q, Niu T, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: a systematic review and meta-analysis. Front Oncol. 2023;13:1071268. https:\/\/doi.org\/10.3389\/fonc.2023.1071268.","journal-title":"Front Oncol"},{"key":"3062_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"G Battipaglia","year":"2021","unstructured":"Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: a retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:209\u201318. https:\/\/doi.org\/10.1002\/cncr.33255.","journal-title":"Cancer"},{"key":"3062_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/bloodadvances.2024014781","volume":"9","author":"N Desai","year":"2025","unstructured":"Desai N, Altareb M, Remberger M, Chen C, Alfaro Moya T, Al-Shaibani E, et al. PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation. Blood Adv. 2025;9:660\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2024014781.","journal-title":"Blood Adv"},{"key":"3062_CR23","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41375-025-02619-1","volume":"39","author":"O Penack","year":"2025","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Benakli M, Kroger N, et al. GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended, a study by the EBMT transplant complications working party. Leukemia. 2025;39:1503\u201311. https:\/\/doi.org\/10.1038\/s41375-025-02619-1.","journal-title":"Leukemia"},{"key":"3062_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/ejh.14291","volume":"113","author":"V Murillo","year":"2024","unstructured":"Murillo V, Charry P, Su\u00e1rez-Lled\u00f3 M, Guardia L, Moreno C, Cid J, et al. Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis. Eur J Haematol. 2024;113:765\u201375. https:\/\/doi.org\/10.1111\/ejh.14291.","journal-title":"Eur J Haematol"},{"key":"3062_CR25","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00277-020-04033-2","volume":"99","author":"I Pasic","year":"2020","unstructured":"Pasic I, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, et al. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2020;99:1377\u201387. https:\/\/doi.org\/10.1007\/s00277-020-04033-2.","journal-title":"Ann Hematol"},{"key":"3062_CR26","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1182\/bloodadvances.2019000155","volume":"3","author":"PH Imus","year":"2019","unstructured":"Imus PH, Tsai HL, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, et al. Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019;3:2608\u201316. https:\/\/doi.org\/10.1182\/bloodadvances.2019000155.","journal-title":"Blood Adv"},{"key":"3062_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41409-018-0367-2","volume":"54","author":"MV Shah","year":"2019","unstructured":"Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, et al. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10\/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transpl. 2019;54:601\u20136. https:\/\/doi.org\/10.1038\/s41409-018-0367-2.","journal-title":"Bone Marrow Transpl"},{"key":"3062_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jtct.2024.05.009","volume":"30","author":"LM Morsink","year":"2024","unstructured":"Morsink LM, Hazenberg CLE, Choi G, de Groot MR, Biswana A, Bellido M, et al. Improved outcome of allogeneic transplantation in older patients treated for myeloid malignancies using post-transplantation cyclophosphamide and reduced duration of immune suppression. Transpl Cell Ther. 2024;30:794\u2013807. https:\/\/doi.org\/10.1016\/j.jtct.2024.05.009.","journal-title":"Transpl Cell Ther"},{"key":"3062_CR29","doi-asserted-by":"publisher","first-page":"334 e331","DOI":"10.1016\/j.jtct.2023.11.018","volume":"30","author":"E Abadir","year":"2024","unstructured":"Abadir E, Othman J, Kwan J, Gottlieb DJ, Kennedy GA, Bajel A, et al. Peripheral blood haploidentical allogeneic stem cell transplantation in older adults with acute myeloid leukemia and myelodysplastic syndromes demonstrates long-term survival, results from Australia and New Zealand Transplant and Cellular Therapies. Transpl Cell Ther. 2024;30:334 e331\u2013334 e337. https:\/\/doi.org\/10.1016\/j.jtct.2023.11.018.","journal-title":"Transpl Cell Ther"},{"key":"3062_CR30","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1182\/bloodadvances.2025016592","volume":"9","author":"YM Aljawai","year":"2025","unstructured":"Aljawai YM, Ramdial J, Smallbone P, Chen G, Kebriaei P, Pasvolsky O, et al. Comparative outcomes of HSCT with posttransplant cyclophosphamide in older adults: the impact of donor type. Blood Adv. 2025;9:5201\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2025016592.","journal-title":"Blood Adv"},{"key":"3062_CR31","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s11357-022-00720-2","volume":"45","author":"KE McGovern","year":"2023","unstructured":"McGovern KE, Sonar SA, Watanabe M, Coplen CP, Bradshaw CM, Nikolich JZ. The aging of the immune system and its implications for transplantation. Geroscience. 2023;45:1383\u20131400. https:\/\/doi.org\/10.1007\/s11357-022-00720-2.","journal-title":"Geroscience"},{"key":"3062_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/hematology.2021000257","volume":"2021","author":"RJ Lin","year":"2021","unstructured":"Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematol Am Soc Hematol Educ Program. 2021;2021:254\u201363. https:\/\/doi.org\/10.1182\/hematology.2021000257.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3062_CR33","unstructured":"EBMT. Guide to completion Allo HCT. https:\/\/www.ebmt.org\/sites\/default\/files\/2026-01\/Guide%20to%20completion%20-%20Allogeneic%20HCT%20Day%200_v2.4.docx.pdf"},{"key":"3062_CR34","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371. https:\/\/doi.org\/10.1182\/blood-2014-01-552984.","journal-title":"Blood"},{"key":"3062_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3062_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317. https:\/\/doi.org\/10.1016\/0002-9343(80)90380-0.","journal-title":"Am J Med"},{"key":"3062_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2991\/chi.d.190503.001","volume":"1","author":"K Culos","year":"2019","unstructured":"Culos K, Byrne M. Salvage therapy after allogeneic hematopoietic cell transplantation: targeted and low-intensity treatment options in myelodysplastic syndrome and acute myeloid leukemia. Clin Hematol Int. 2019;1:94\u2013100. https:\/\/doi.org\/10.2991\/chi.d.190503.001.","journal-title":"Clin Hematol Int"},{"key":"3062_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.571884","volume":"11","author":"GDE Cuvelier","year":"2020","unstructured":"Cuvelier GDE, Li A, Drissler S, Kariminia A, Abdossamadi S, Rozmus J, et al. Age-related differences in the biology of chronic graft-versus-host disease after hematopoietic stem cell transplantation. Front Immunol. 2020;11. 571884. https:\/\/doi.org\/10.3389\/fimmu.2020.571884.","journal-title":"Front Immunol"},{"key":"3062_CR39","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.bbmt.2018.08.015","volume":"24","author":"MC Cupit-Link","year":"2018","unstructured":"Cupit-Link MC, Arora M, Wood WA, Hashmi SK. Relationship between aging and hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2018;24:1965\u201370. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.015.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3062_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","volume":"3","author":"R Dulery","year":"2021","unstructured":"Dulery R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 2021;3:250\u20139. https:\/\/doi.org\/10.1016\/j.jaccao.2021.02.011.","journal-title":"JACC CardioOncol"},{"key":"3062_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101092","volume":"62","author":"M Mikulska","year":"2023","unstructured":"Mikulska M, Bartalucci C, Raiola AM, Oltolini C. Does PTCY increase the risk of infections? Blood Rev. 2023;62:101092. https:\/\/doi.org\/10.1016\/j.blre.2023.101092.","journal-title":"Blood Rev"},{"key":"3062_CR42","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1111\/bjh.70124","volume":"207","author":"N Desai","year":"2025","unstructured":"Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, et al. A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation. Br J Haematol. 2025;207:2049\u201358. https:\/\/doi.org\/10.1111\/bjh.70124.","journal-title":"Br J Haematol"},{"key":"3062_CR43","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00277-025-06305-1","volume":"104","author":"Y Jia","year":"2025","unstructured":"Jia Y, Xia X, Yang J, Cai Y, Tong Y, Qiu H, et al. Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globulin (ATG)\/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis. Ann Hematol. 2025;104:1857\u201366. https:\/\/doi.org\/10.1007\/s00277-025-06305-1.","journal-title":"Ann Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03062-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03062-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03062-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:18:54Z","timestamp":1791285534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03062-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":43,"alternative-id":["3062"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03062-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OP has received honoraria or travel support from Alexion, Gilead, Jazz, MSD, Neovii, Novartis, Pfizer and Therakos; research support from Incyte, Gilead and Priothera; and he is a member of advisory boards to Apogepha, Alexion, Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Orca Bio, Priothera, Sanofi, Shionogi and SOBI. HS reports having received personal fees from Incyte, Novartis, MAAT Pharma, Mallinckrodt Pharmaceuticals, Sanofi, BeiGene and the Belgian Hematological Society (BHS), as well as research funding from Sanofi, all paid to her institution and not directly related to this work. She has also received non-financial support from Pfizer, Sanofi, AbbVie, the EBMT (European Society for Blood and Marrow Transplantation), the IACH (International Academy for Clinical Hematology) and the CIBMTR (Center for International Bone Marrow Transplantation Research). All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. No study346 specific ethics committee approval was required for this retrospective analysis of the EBMT Registry. Data were collected within the EBMT Registry after informed consent had been obtained from all participants in accordance with local regulations and institutional requirements at participating centres.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}